Novo Holdings
Novo Holdings, established in 1999 and based in Copenhagen, is the asset manager for the Novo Nordisk Foundation, overseeing its wealth and investments. The company primarily focuses on the life sciences sector, investing across various stages of company development, from early-stage ventures to established firms. Novo Holdings also manages a diversified portfolio of financial investments, including equity and fixed income securities. It is recognized as a leading life science investor globally and aims to generate long-term value to support the Foundation's grant obligations for medical and scientific research. Additionally, it plays a pivotal role in the Novo Group, maintaining a significant influence over its associated companies, including Novo Nordisk and Novozymes, while ensuring compliance with the group’s shared values and management principles. Through initiatives like Novo Seeds, the firm supports early-stage applied research in Scandinavia, further solidifying its commitment to advancing health and welfare through strategic investments.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
AMRA is an international medical technology company, the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service.They collaborate with world-leading pharmaceutical organizations, biobanks and population cohorts, research institutions, hospitals, and clinics, aiding in the advancement of metabolic research and therapeutic application. With more accurate knowledge about our bodies, AMRA assists the world's medical leaders in predicting and preventing disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.